Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Treatment.com International ( (TSE:TRUE) ) is now available.
Rocket Doctor Inc. has launched a virtual care partnership with Central California Alliance for Health, a Medi-Cal managed care plan serving approximately 450,000 members in several California counties. This initiative aims to reduce emergency room visits and improve access to care for underserved populations by providing tele-urgent, primary, and specialty care services through Rocket Doctor’s digital platform. The collaboration allows Rocket Doctor physicians to be fully credentialed within the Alliance’s provider network, enhancing healthcare accessibility and equity for Medi-Cal beneficiaries.
Spark’s Take on TSE:TRUE Stock
According to Spark, TipRanks’ AI Analyst, TSE:TRUE is a Underperform.
Treatment.com International is struggling financially, with persistent losses and negative cash flow overshadowing recent revenue growth. The stock is technically weak, and valuation metrics highlight its unprofitable status. However, recent corporate events, including strategic acquisitions and partnerships, provide some potential for future growth, although they have not yet addressed the core financial challenges.
To see Spark’s full report on TSE:TRUE stock, click here.
More about Treatment.com International
Rocket Doctor Inc. is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Utilizing proprietary software and AI-powered tools, Rocket Doctor focuses on delivering high-quality comprehensive care remotely, particularly to underserved and remote communities across North America.
Average Trading Volume: 114,206
Technical Sentiment Signal: Sell
Current Market Cap: C$27.18M
See more data about TRUE stock on TipRanks’ Stock Analysis page.